The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Assessing potential of psilocybin for depressive disorders
Abstract
INTRODUCTION: There has been increasing interest in the role psilocybin may play in the treatment of depressive disorders. Several clinical trials have shown psilocybin to have efficacy in reducing symptoms of depression. AREASCOVERED: We discuss the current understanding of psilocybin's therapeutic mechanism of action and review existing clinical data investigating psilocybin as a novel therapeutic agent for the treatment of depression. EXPERT OPINION: There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 3×
“Numerous studies have investigated psilocybin as a novel therapeutic compound for the treatment of depression [10–14], and favorable findings from a recent phase IIb clinical trial have paved the way for the world’s first phase 3 clinical trial of psilocybin for TRD [15].”
BackgroundSelf-citationEpidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 1×
“Recent reports found that Major Depressive Disorder (MDD) was diagnosed in 10% of the general population in the United States in the past 12 months [3], and about one in three patients seeking treatment for MDD fail to respond to+ adequate trials of at least two antidepressant medications,…”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“Multiple clinical trials have found psilocybin to be associated with persistent, positive effects on mood and behavior [21,22], leading to scientific enthusiasm about its potential to treat depression.”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“In 2016, Carhart-Harris et al. [11] published an open-label, single-arm pilot study investigating the feasibility of psilocybin for TRD. Participants received two oral doses of psilocybin, 10 and 25 mg, 7 days apart with psychological support.”
BackgroundDepression Is the Leading Cause of Disability Around the World
Friedrich, M. J. (2017) · JAMA · doi:10.1001/jama.2017.3826 · Cited by 1,459
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Research works printed but not linked: 2
- Agrawal M Emanuel E Richards B et al. Assessment of psilocybin therapy for patients with cancer and major depression disorder. JAMA Oncol [Internet]. 2023 [cited 2023 Jun 5]; Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2803623.
- Paglia C. Cults and cosmic consciousness: religious vision in the American. Arion. 2003;10(3): 1–111.
Cited by
Hashimoto, K. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01770-7 · Cited by 61
Kwon, K. J., Kim, H. Y., Han, S., & Shin, C. Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111338 · Cited by 24
Beyond psychedelics: set and setting in general psychiatric practice
Kozak, Z., & Miller, C. W. T. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2419662 · Cited by 14
Self-citationHilal, F. F., Jeanblanc, J., Deschamps, C., Naassïla, M., Pierrefiche, O., & Hamida, S. B. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02757-3 · Cited by 9
Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer
Thrul, J., Kozak, Z., Carducci, M. A., Garcia‐Romeu, A., & Yaden, D. B. (2024) · Cancer · doi:10.1002/cncr.35127 · Cited by 6
Self-citation
Metadata
- Authors
- Kozak, Z., Johnson, M. W., & Aaronson, S. T.
- Affiliations
- University of Maryland, Baltimore (US)
- Johns Hopkins University (US)
- Corresponding author
- Aaronson, Scott T.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2023-10-03
- Volume
- 32
- Issue
- 10
- Pages
- 887-900
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W4387866078
- Cited by
- 11
- References
- 74
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 1
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, depression, treatment-resistant depression, psychedelic therapy, clinical trials, benefits and risks, antidepressant efficacy
- MeSH terms
- Hallucinogens, Humans, Psilocybin, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessing potential of psilocybin for depressive disorders. https://app.cochat.ai/papers/10.1080/13543784.2023.2273493
- The paper
- Kozak, Z., Johnson, M. W., & Aaronson, S. T. (2023). Assessing potential of psilocybin for depressive disorders. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2023.2273493
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.